Vaidya Sane Ayurved Laboratories Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Vaidya Sane Ayurved Laboratories has been growing earnings at an average annual rate of 27.4%, while the Healthcare industry saw earnings growing at 29.2% annually. Revenues have been growing at an average rate of 11% per year. Vaidya Sane Ayurved Laboratories's return on equity is 3.6%, and it has net margins of 2%.
Belangrijke informatie
27.4%
Groei van de winst
26.3%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 29.4% |
| Inkomstengroei | 11.0% |
| Rendement op eigen vermogen | 3.6% |
| Nettomarge | 2.0% |
| Laatste winstupdate | 31 Mar 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Vaidya Sane Ayurved Laboratories geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 993 | 20 | 458 | 0 |
| 31 Dec 23 | 1,020 | 26 | 454 | 0 |
| 30 Sep 23 | 1,047 | 33 | 450 | 0 |
| 30 Jun 23 | 1,019 | 41 | 437 | 0 |
| 31 Mar 23 | 992 | 48 | 423 | 0 |
| 31 Dec 22 | 940 | 48 | 336 | 0 |
| 30 Sep 22 | 887 | 48 | 248 | 0 |
| 30 Jun 22 | 817 | 42 | 258 | 0 |
| 31 Mar 22 | 747 | 35 | 268 | 0 |
| 31 Mar 21 | 523 | 4 | 166 | 0 |
| 31 Mar 20 | 752 | -6 | 371 | 0 |
| 31 Mar 19 | 625 | 5 | 307 | 0 |
| 31 Mar 18 | 376 | 11 | 166 | 0 |
Kwaliteitswinsten: MADHAVBAUG has a high level of non-cash earnings.
Groeiende winstmarge: MADHAVBAUG's current net profit margins (2%) are lower than last year (4.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: MADHAVBAUG's earnings have grown significantly by 27.4% per year over the past 5 years.
Versnelling van de groei: MADHAVBAUG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: MADHAVBAUG had negative earnings growth (-59%) over the past year, making it difficult to compare to the Healthcare industry average (30.6%).
Rendement op eigen vermogen
Hoge ROE: MADHAVBAUG's Return on Equity (3.6%) is considered low.